本網(wǎng)站銷售的所有產(chǎn)品僅用于工業(yè)應(yīng)用或者科學(xué)研究等非醫(yī)療目的,不可用于人類或動(dòng)物的臨床診斷或者治療,非藥用,非食用。
Dupilumab
英文名:
Cas號(hào):1190264-60-8
Cas號(hào):1190264-60-8
檢測(cè)信息查詢
| 貨號(hào) | 規(guī)格 | 貨期 | 庫(kù)存 | 價(jià)格 | 促銷價(jià) | 訂購(gòu) |
| 1308132501-1mg | 0 | ¥0 | ||||
| 1308132501-5mg | 0 | ¥0 | ||||
| 1308132501-25mg | 0 | ¥0 |
| 別 名 | |
| Cas號(hào) | 1190264-60-8 |
| M D L | |
| 分子式 | |
| 分子量 | |
| 產(chǎn)品參數(shù) | Description
Dupilumab (REGN-668) is a fully human mAb to IL-4 receptor α (IL-4Rα) that inhibits both IL-4 and IL-13 signaling, markedly improved moderate-to-severe atopic dermatitis[1]. IC50 & Target IL-4 and IL-13 signaling[1] Storage Please store the product under the recommended conditions in the Certificate of Analysis. References [1]. Hamilton JD, et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol. 2014 Dec;134(6):1293-1300. |
| 性狀 | Dupilumab (REGN-668) 是針對(duì) IL-4 受體α (IL-4Rα) 的完全人類單克隆抗體,可抑制 IL-4 和 IL-13 信號(hào)轉(zhuǎn)導(dǎo),顯著改善中度至重度特應(yīng)性皮炎。 |
| 貯存 |
- Obinutuzumab
- Reslizumab 241473-69-8
- 那他珠單抗 189261-10-7
- BENRALIZUMAB 1044511-01-4
- Dupilumab 1190264-60-8
- 重組人FGF-ACIDIC
- Recombinant Human Amphiregulin
- Recombinant Human B cell Activating Factor/TNFSF13B
- 重組人FGF-BASIC
小程序掃碼下單
滬公網(wǎng)安備 31012002003054號(hào)